Publication: Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.
No Thumbnail Available
Identifiers
Date
2019-05-21
Authors
Pérez-Belmonte, Luis M
Osuna-Sánchez, Julio
Millán-Gómez, Mercedes
López-Carmona, María D
Gómez-Doblas, Juan J
Cobos-Palacios, Lidia
Sanz-Cánovas, Jaime
Barbancho, Miguel A
Lara, José P
Jiménez-Navarro, Manuel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Introduction: The use of dipeptidyl peptidase-4 inhibitors in hospitalized patients is an area of active research. We aimed to compare the efficacy and the safety of the basal-bolus insulin regimen versus linagliptin-basal insulin in non-critically ill non-cardiac surgery patients in a real-world setting. Methods: We enrolled patients with type 2 diabetes hospitalized in non-cardiac surgery departments with admission glycated haemoglobin level 200 mg/dL (p = .199), and treatment failures (p = .395). Total daily insulin and number of daily insulin injections were lower in the linagliptin-basal group (both p
Description
MeSH Terms
Aged
Blood Glucose
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Drug Therapy, Combination
Female
Glycated Hemoglobin
Hospitalization
Humans
Hypoglycemia
Hypoglycemic Agents
Insulin
Linagliptin
Male
Middle Aged
Safety
Spain
Treatment Failure
Treatment Outcome
Blood Glucose
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Drug Therapy, Combination
Female
Glycated Hemoglobin
Hospitalization
Humans
Hypoglycemia
Hypoglycemic Agents
Insulin
Linagliptin
Male
Middle Aged
Safety
Spain
Treatment Failure
Treatment Outcome
DeCS Terms
CIE Terms
Keywords
Diabetes mellitus, inpatient hyperglycaemia, linagliptin, non-cardiac surgery